Home > Publications > Medical Specialty > Internal Medicine > Medical Oncology > Lung Cancer > Lung Cancer Research Review, Issue 82
Lung Cancer Research Review, Issue 82

Lung Cancer Research Review, Issue 82

In this issue:

Can RT to residual disease sites prolong disease control
Activity and safety of tarlatamab plus PD-L1 inhibitor
Should BRAF and MEK inhibitors or ICIs be prioritised
Safety and efficacy of BOS172738
Osimertinib plus chemotherapy versus placebo plus chemotherapy
Long-term results of lorlatinib
Antitumour efficacy of sunvozertinib
TFS from nivolumab plus ipilimumab
Efficacy of COCOON prophylactic regimen
Taxanes versus gemcitabine

You need to be logged in to access this content.

Sagun-Parakh

Expert contributor

Dr Sagun Parakh

Dr Sagun Parakh is a Consultant Medical Oncologist at Austin Hospital, specialising in lung cancer and primary brain tumours. After obtaining his fellowship, he completed his PhD at Olivia Newton-John Cancer Research Institute (ONJCRI) focusing on the development of a novel first-in-class anti-ErbB2 antibody. He is the head of the Lung Oncology Clinic at the […]

Latest Publications and Videos

Stay up to date with our latest clinical information.

Explore Research Review Publications and Videos

Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry. 

Find Reviews in Your Clinical Area
Please select your country of practice.

It looks like you are closest to our New Zealand site.

Terms and Conditions

Website terms of use 

By using our website, you agree to follow these terms and conditions. 

 

Privacy policy 

We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms. 

 

Copyright and use of website content 

The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use. 

You cannot:  copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission. 

 

Links to third-party websites 

The Research Review website may link to third-party websites for your convenience. However: 

We do not endorse or approve their products, services, or actions. 

We are not responsible for their content or how they operate. 

There is no formal partnership between us and third parties unless we clearly state otherwise. 

 

Disclaimer and limitation of liability 

We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date. 

To the fullest extent allowed by law, we are not responsible for: 

Any loss, damage, or costs you may suffer from using (or being unable to use) our website. 

Any decisions you make based on the information provided. 

Any business losses, such as lost profits, lost data, or business interruptions. 

 

Governing law 

These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.